- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 18.02. | Topps Tiles - Nearing resolution of CMA review | 298 | The announcement that the Competition and Markets Authority (CMA) has found Topps Tiles' (TPT's) acquisition of CTD Tiles generates no competition concerns in the majority of the areas reviewed should... ► Artikel lesen | ||
| 18.02. | British American Tobacco - Moving to a smokeless world | 1.036 | British American Tobacco's (BAT's) strategy is to become a predominantly smokeless business, generating more than 50% of revenue (FY24: 17.5%) from smokeless products by FY35. The industry backdrop... ► Artikel lesen | ||
| 18.02. | IRLAB Therapeutics (STO: IRLAB-A) announces loan term extension and new shareholder loan | 296 | IRLAB has renegotiated its loan terms with FENJA Capital, allowing it to extend duration of the SEK55m loan from May 2025 to 31 December 2025 and potentially to 30 June 2026 (for an additional fee of... ► Artikel lesen | ||
| 17.02. | Theon International - Strong FY24 results; FY25 guidance confirmed | 384 | Theon has reported a strong set of maiden results as a listed company, along with good growth in order backlog, supporting positive guidance for FY25. Equally important are the operational milestones... ► Artikel lesen | ||
| 17.02. | GSK's (LSE: GSK) five-in-one vaccine approved by the FDA | 450 | GSK's five-in-one meningococcal vaccine, Penmenvy, has been approved by the US FDA for the treatment of meningitis, an indication that, in extreme cases, can lead to deadly brain swelling. More specifically... ► Artikel lesen | ||
| 17.02. | Topps Tiles (LSE:TPT) - CTD Tiles acquisition generated no competition concerns in majority of areas reviewed | 266 | Topps Tiles has announced the Competition and Markets Authority (CMA) found the proposed acquisition generated no competition concerns in the majority of areas reviewed. The CMA has identified possible... ► Artikel lesen | ||
| 14.02. | Knowit - Positive signs amid strong headwinds | 344 | Knowit reported signs of recovery at the end of a challenging 2024 that saw headcount reduced by 10%. Management has not only downsized the business but also taken steps to improve efficiency. This... ► Artikel lesen | ||
| 14.02. | Oryzon (BME: ORY) publishes REIMAGINE results in prestigious journal | 326 | Oryzon Genomics has announced the publication of the final Phase IIa REIMAGINE results in the journal Psychiatry and Clinical Neurosciences. The REIMAGINE trial evaluated the safety and efficacy of... ► Artikel lesen | ||
| 14.02. | Pinewood Technologies (LSE: PINE) signs significant new contract | 330 | Pinewood Technologies has signed a five-year contract with Global Auto Holdings (GAH) to implement the Pinewood Automotive Intelligence platform into all of its owned dealerships in the UK, North America... ► Artikel lesen | ||
| 13.02. | Actinogen Medical - XanaMIA Phase IIb/III study marches on | 275 | Actinogen Medical continues to make progress with its 36-week XanaMIA Phase IIb/III study assessing Xanamem in patients with biomarker-positive mild-to-moderate Alzheimer's disease (AD). The company... ► Artikel lesen | ||
| 13.02. | Mendus - Focus firmly on pivotal-stage readiness in 2025 | 276 | Mendus's FY24 results and subsequent management presentation highlighted its focus on advancing lead asset, vididencel, to pivotal-stage readiness. Backed by robust long-term monotherapy data from ADVANCE... ► Artikel lesen | ||
| 13.02. | Creo Medical - Consumables business divestment concludes | 228 | Creo Medical has completed the sale of the majority (51%) stake in its European consumable business to Chinese medical device manufacturer Micro-Tech for net proceeds of c €30m (c £25m). The deal valued... ► Artikel lesen | ||
| 13.02. | Cereno Scientific - CS014 achieves another Phase I milestone | 204 | Cereno Scientific's second pipeline asset, CS014, continues to make steady progress through the clinic, with the company successfully completing the single ascending dose (SAD) part of the Phase I study... ► Artikel lesen | ||
| 13.02. | British American Tobacco (LSE: BATS) - FY24 results in line | 659 | British American Tobacco (BAT) navigated a year of transformation in 2024, with its pivot towards a smokeless future gaining momentum. The company added 3.6 million new adult users of its smokeless... ► Artikel lesen | ||
| 13.02. | RELX (LSE: REL) - Good momentum into FY25 | 306 | RELX has turned in a very good performance for 2024, with underlying revenue growth of 7% and a step-up in adjusted operating margin from 33.1% to 33.9%. Encouragingly, there was progress in margin... ► Artikel lesen | ||
| 13.02. | Immix Biopharma - NXC-201 receives FDA RMAT designation | 231 | Immix Biopharma has been granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA) for the company's novel sterically optimized CAR-T treatment... ► Artikel lesen | ||
| 12.02. | Claranova - Stable performance in H125 | 359 | Claranova's underlying revenue was essentially flat year-on-year in H125. While underlying revenue grew 3% for Avanquest, PlanetArt felt the effects of a shorter holiday season in the US, with underlying... ► Artikel lesen | ||
| 12.02. | S&U - A tale of two businesses | 283 | S&U published an update on trading to 31 January (end-FY25) and will release its annual results on 15 April. Group performance continues to be characterised by strong growth in the property lending... ► Artikel lesen | ||
| 12.02. | ADS-TEC Energy - Positive progress in 2024 | 382 | ADS-TEC reported record revenue, albeit below previous guidance, despite 2024 being a more challenging period for EVs and associated infrastructure-related companies and some revenue deferrals into... ► Artikel lesen | ||
| 12.02. | Lime Technologies (STO: LIME) hits FY24 targets | 261 | Lime Technologies reported Q424 revenue growth of 18.9% y-o-y, with an EBITA margin of 25.6% and growth in annual recurring revenue of 30% y-o-y. For FY24, revenue was 18.8% higher (beating the 18%... ► Artikel lesen | ||
| 11.02. | MJ Gleeson (LON: GLEE) - Interims point to improving H2 | 213 | MJ Gleeson has delivered a resilient first-half performance despite a subdued market, with Gleeson Homes growing sales volumes and increasing its forward order book. The 10% rise in Gleeson Homes' revenue... ► Artikel lesen | ||
| 11.02. | Dunelm Group (LSE: DNLM) - H125 results resilient and CEO to retire | 348 | Dunelm Group's H125 results reflect a resilient performance despite macroeconomic pressures, with low-single-digit sales growth and limited profit growth. The 2.4% revenue growth to £894m underscores... ► Artikel lesen | ||
| 10.02. | VEON - An innovative approach to frontier telecoms | 3.863 | VEON is a frontier market telecommunications operator offering traditional mobile and internet, and innovative digital services such as online payments, music and TV streaming, and IT services. It has... ► Artikel lesen | ||
| 10.02. | Safari Investments - Portfolio optimisation to enhance value | 205 | Safari Investments (SAR) is a retail property specialist that owns and operates suburban shopping centres in South Africa and Namibia: four small regional shopping centres and four community centres.... ► Artikel lesen | ||
| 10.02. | Zinc (LSE: ZIN) starts new year with strong momentum | 384 | Zinc's full-year trading update indicates adjusted EBITDA up 50% at £1.5m, on revenues down from £40m to £32m as the business changes shape, with non-core elements exited. The group has had a series... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
